Bioequivalence study of two nevirapine tablet formulations in human immunodeficiency virus-infected patients
Bioequivalence study of two nevirapine tablet formulations in human immunodeficiency virus-infected patients
Leído
5683
Vecesse ha leído el artículo
2852
Total PDF
2831
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 10 | 9 | 19 |
| 2025 5 | 29 | 40 | 69 |
| 2025 4 | 22 | 41 | 63 |
| 2025 3 | 27 | 40 | 67 |
| 2025 2 | 24 | 34 | 58 |
| 2025 1 | 16 | 34 | 50 |
| 2024 12 | 15 | 26 | 41 |
| 2024 11 | 20 | 39 | 59 |
| 2024 10 | 21 | 55 | 76 |
| 2024 9 | 19 | 29 | 48 |
| 2024 8 | 28 | 39 | 67 |
| 2024 7 | 25 | 27 | 52 |
| 2024 6 | 28 | 31 | 59 |
| 2024 5 | 21 | 35 | 56 |
| 2024 4 | 16 | 48 | 64 |
| 2024 3 | 32 | 45 | 77 |
| 2024 2 | 16 | 48 | 64 |
| 2024 1 | 11 | 53 | 64 |
| 2023 12 | 13 | 40 | 53 |
| 2023 11 | 9 | 48 | 57 |
| 2023 10 | 14 | 60 | 74 |
| 2023 9 | 12 | 28 | 40 |
| 2023 8 | 10 | 15 | 25 |
| 2023 7 | 21 | 22 | 43 |
| 2023 6 | 38 | 54 | 92 |
| 2023 5 | 11 | 54 | 65 |
| 2023 4 | 17 | 45 | 62 |
| 2023 3 | 5 | 22 | 27 |
| 2023 2 | 10 | 33 | 43 |
| 2022 1 | 9 | 12 | 21 |
| 2022 12 | 6 | 44 | 50 |
| 2022 11 | 16 | 42 | 58 |
| 2022 10 | 9 | 24 | 33 |
| 2022 9 | 14 | 49 | 63 |
| 2022 8 | 5 | 24 | 29 |
| 2022 7 | 12 | 20 | 32 |
| 2022 6 | 8 | 27 | 35 |
| 2022 5 | 12 | 19 | 31 |
| 2022 4 | 17 | 34 | 51 |
| 2022 3 | 16 | 36 | 52 |
| 2022 2 | 11 | 15 | 26 |
| 2021 1 | 7 | 20 | 27 |
| 2021 12 | 6 | 27 | 33 |
| 2021 11 | 10 | 25 | 35 |
| 2021 10 | 9 | 15 | 24 |
| 2021 9 | 6 | 22 | 28 |
| 2021 8 | 11 | 18 | 29 |
| 2021 7 | 8 | 19 | 27 |
| 2021 6 | 20 | 24 | 44 |
| 2021 5 | 8 | 23 | 31 |
| 2021 4 | 57 | 70 | 127 |
| 2021 3 | 26 | 27 | 53 |
| 2021 2 | 12 | 16 | 28 |
| 2020 1 | 9 | 20 | 29 |
| 2020 12 | 7 | 26 | 33 |
| 2020 11 | 5 | 13 | 18 |
| 2020 10 | 5 | 15 | 20 |
| 2020 9 | 14 | 17 | 31 |
| 2020 8 | 15 | 19 | 34 |
| 2020 7 | 8 | 11 | 19 |
| 2020 6 | 3 | 10 | 13 |
| 2020 5 | 16 | 14 | 30 |
| 2020 4 | 7 | 7 | 14 |
| 2020 3 | 3 | 13 | 16 |
| 2020 2 | 8 | 11 | 19 |
| 2020 1 | 13 | 15 | 28 |
| 2019 12 | 17 | 24 | 41 |
| 2019 11 | 3 | 4 | 7 |
| 2019 10 | 12 | 7 | 19 |
| 2019 9 | 16 | 4 | 20 |
| 2019 8 | 9 | 17 | 26 |
| 2019 7 | 14 | 34 | 48 |
| 2019 6 | 26 | 37 | 63 |
| 2019 5 | 57 | 39 | 96 |
| 2019 4 | 30 | 29 | 59 |
| 2019 3 | 6 | 5 | 11 |
| 2019 2 | 9 | 8 | 17 |
| 2019 1 | 12 | 7 | 19 |
| 2018 12 | 9 | 9 | 18 |
| 2018 11 | 10 | 10 | 20 |
| 2018 10 | 14 | 7 | 21 |
| 2018 9 | 6 | 7 | 13 |
| 2018 8 | 0 | 4 | 4 |
| 2018 7 | 2 | 2 | 4 |
| 2018 6 | 4 | 1 | 5 |
| 2018 5 | 5 | 1 | 6 |
| 2018 2 | 3 | 5 | 8 |
| 2018 1 | 1 | 5 | 6 |
| 2017 12 | 0 | 1 | 1 |
| 2017 11 | 5 | 1 | 6 |
| 2017 10 | 4 | 1 | 5 |
| 2017 9 | 3 | 5 | 8 |
| 2017 8 | 10 | 2 | 12 |
| 2017 7 | 11 | 2 | 13 |
| 2017 6 | 5 | 9 | 14 |
| 2017 5 | 7 | 1 | 8 |
| 2017 4 | 10 | 7 | 17 |
| 2017 3 | 8 | 45 | 53 |
| 2017 2 | 12 | 11 | 23 |
| 2016 1 | 4 | 6 | 10 |
| 2016 12 | 21 | 13 | 34 |
| 2016 11 | 23 | 7 | 30 |
| 2016 10 | 22 | 14 | 36 |
| 2016 9 | 20 | 4 | 24 |
| 2016 8 | 18 | 2 | 20 |
| 2016 7 | 13 | 2 | 15 |
| 2016 6 | 24 | 26 | 50 |
| 2016 5 | 8 | 62 | 70 |
| 2016 4 | 16 | 28 | 44 |
| 2016 3 | 6 | 38 | 44 |
| 2016 2 | 18 | 36 | 54 |
| 2015 1 | 18 | 42 | 60 |
| 2015 12 | 8 | 20 | 28 |
| 2015 11 | 8 | 24 | 32 |
| 2015 10 | 32 | 40 | 72 |
| 2015 9 | 10 | 18 | 28 |
| 2015 8 | 12 | 14 | 26 |
| 2015 7 | 22 | 12 | 34 |
| 2015 6 | 8 | 16 | 24 |
| 2015 5 | 22 | 8 | 30 |
| 2015 4 | 32 | 26 | 58 |
| 2015 3 | 12 | 12 | 24 |
| 2015 2 | 20 | 8 | 28 |
| 2015 1 | 32 | 4 | 36 |
| 2014 12 | 28 | 4 | 32 |
| 2014 11 | 16 | 8 | 24 |
| 2014 10 | 34 | 4 | 38 |
| 2014 9 | 22 | 8 | 30 |
| 2014 8 | 42 | 6 | 48 |
| 2014 7 | 26 | 8 | 34 |
| 2014 6 | 34 | 8 | 42 |
| 2014 5 | 20 | 6 | 26 |
| 2014 4 | 30 | 4 | 34 |
| 2014 3 | 26 | 0 | 26 |
| 2014 2 | 42 | 4 | 46 |
| 2014 1 | 18 | 0 | 18 |
| 2013 12 | 30 | 2 | 32 |
| 2013 11 | 30 | 4 | 34 |
| 2013 10 | 30 | 4 | 34 |
| 2013 9 | 22 | 4 | 26 |
| 2013 8 | 30 | 8 | 38 |
| 2013 7 | 28 | 0 | 28 |
| 2007 4 | 586 | 0 | 586 |
Mostrar todo
